TP53 and lung carcinoma: Although not currently a therapeutic target, routine inclusion of TP53 mutation testing by NSG may more accurately determine the effects of this tumor suppressor gene both alone and in combination with other driver mutations in lung cancer and whether there is an interaction with treatment.